Expression of PARP-1 in Multiple Sclerosis Patients

Not Applicable

Completed

• Conditions: Multiple Sclerosis
• Interventions: Genetic: Blood sampling

• Registration Number: NCT05196425
• Lead Sponsor: Sohag University

Brief Summary

This study will explore the expression of PARP-1 in optic neuritis of multiple sclerosis patients.

The data will be collected from Sohag University hospital in the period from the start of August 2021 to the end of December 2021.

The study protocol will be approved by the Scientific Research Ethical Committee, Faculty of Medicine, Sohag University.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-08-01
• Study First Submitted: 2021-12-07
• Study First Submitted QC: 2022-01-18
• Study First Posted: 2022-01-19
• Primary Completion: 2022-03-30
• Study Completion: 2022-04-30
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-29
• Last Update Posted: 2025-05-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Patients with multiple sclerosis with or without optic neuritis Multiple sclerosis will be diagnosed according to the McDonald criteria

Exclusion Criteria

• • Isolated optic neuritis.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ms without optic neuritis	Blood sampling	-
MS with optic neuritis	Blood sampling	-
Control group	Blood sampling	-

Primary Outcome Measures

Name	Time	Method
measure PARP-1 mRNA	2 weeks	measure PARP-1 mRNA

Secondary Outcome Measures

Name	Time	Method
Optic nerve, RNFL and GCC layer affection by MS	2 weeks	Optic nerve Retinal nerve fibre layer (RNFL) in um; ) and Ganglion cell complex (GCC) layer affection in um by MS in correlation to PARP-1 mRNA

Trial Locations

Locations (1)

Elshimaa A.Mateen; 🇪🇬 Sohag, Egypt